(Q36378596)

13 August 2017

1 reference

title

Vertically acquired paediatric coinfection with HIV and hepatitis C virus (English)

1 reference

13 August 2017

1 reference

1 reference

2

1 reference

13 August 2017

3

1 reference

13 August 2017

Kirsty England

1

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Lancet Infectious Diseases

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

83-90

1 reference

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

HIV and hepatitis C virus co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Mechanisms and timing of mother-to-child transmission of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Epidemiology of HIV infection in the newborn

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Prevention of pediatric human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Advances in the prevention of vertical transmission of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Mother to infant transmission of coinfection by human immunodeficiency virus and hepatitis C virus: prevalence and clinical manifestations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

A prospective study on mother-to-infant transmission of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatitis C virus infection in the mothers and infants cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

When does mother to child transmission of hepatitis C virus occur?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Gender and race do not alter early-life determinants of clinical disease progression in HIV-1 vertically infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Impact of chronic hepatitis C on HIV-1 disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Three broad modalities in the natural history of vertically acquired hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatitis C and HIV-1 coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Chronic hepatitis C in children: the pathological and clinical spectrum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

HIV and hepatitis C virus: facts and controversies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Hepatitis C virus infection: the new global epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970381-4

7 January 2021

10.1016/S1473-3099(06)70381-4

Identifiers

DOI

1 reference

13 August 2017

1 reference